CA2919690C - Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate - Google Patents
Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Download PDFInfo
- Publication number
- CA2919690C CA2919690C CA2919690A CA2919690A CA2919690C CA 2919690 C CA2919690 C CA 2919690C CA 2919690 A CA2919690 A CA 2919690A CA 2919690 A CA2919690 A CA 2919690A CA 2919690 C CA2919690 C CA 2919690C
- Authority
- CA
- Canada
- Prior art keywords
- signature
- pathways
- cto
- response
- pharmacodynamic biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/957,720 | 2013-08-02 | ||
| US13/957,720 US10378059B2 (en) | 2013-08-02 | 2013-08-02 | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
| PCT/US2014/048905 WO2015017545A1 (en) | 2013-08-02 | 2014-07-30 | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2919690A1 CA2919690A1 (en) | 2015-02-05 |
| CA2919690C true CA2919690C (en) | 2021-11-02 |
Family
ID=52428197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2919690A Active CA2919690C (en) | 2013-08-02 | 2014-07-30 | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10378059B2 (https=) |
| EP (1) | EP3027776B1 (https=) |
| JP (1) | JP6913459B2 (https=) |
| KR (1) | KR102389934B1 (https=) |
| CN (1) | CN105531380B (https=) |
| AU (1) | AU2014296212B2 (https=) |
| CA (1) | CA2919690C (https=) |
| IL (1) | IL243894B (https=) |
| WO (1) | WO2015017545A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10882841B2 (en) | 2016-03-01 | 2021-01-05 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| JP6889009B2 (ja) * | 2017-04-13 | 2021-06-18 | 浜松ホトニクス株式会社 | 画像取得システム及び画像取得方法 |
| US20220168276A1 (en) * | 2020-08-05 | 2022-06-02 | Tactical Therapeotics Inc. | Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69633566T2 (de) * | 1995-07-21 | 2005-12-08 | Savvipharm Inc. | Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen |
| US20030170720A1 (en) * | 2001-01-23 | 2003-09-11 | Van Der Kuyl Antoinette Cornelia | Means and methods for treatment evaluation |
| US8137910B2 (en) | 2002-05-03 | 2012-03-20 | Duke University | Method of regulating gene expression |
| US8450057B2 (en) | 2006-08-14 | 2013-05-28 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| US7750018B2 (en) * | 2006-12-06 | 2010-07-06 | Tactical Therapeutics, Inc | Use of carboxiamidotriazole (CAI) orotate in macular degeneration |
| JP2010522567A (ja) | 2007-03-28 | 2010-07-08 | メダレックス インコーポレーティッド | 遺伝子増幅および発現の方法 |
| WO2009120561A2 (en) * | 2008-03-22 | 2009-10-01 | Merck & Co., Inc. | Methods and gene expression signature for assessing growth factor signaling pathway regulation status |
| NZ598482A (en) * | 2009-09-04 | 2014-05-30 | Tactical Therapeutics Inc | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
| US8877785B2 (en) * | 2009-09-04 | 2014-11-04 | Tactical Therapeutics Inc | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate |
| WO2012135845A1 (en) * | 2011-04-01 | 2012-10-04 | Qiagen | Gene expression signature for wnt/b-catenin signaling pathway and use thereof |
-
2013
- 2013-08-02 US US13/957,720 patent/US10378059B2/en active Active
-
2014
- 2014-07-30 JP JP2016531859A patent/JP6913459B2/ja active Active
- 2014-07-30 KR KR1020167002926A patent/KR102389934B1/ko active Active
- 2014-07-30 AU AU2014296212A patent/AU2014296212B2/en active Active
- 2014-07-30 CN CN201480050189.3A patent/CN105531380B/zh active Active
- 2014-07-30 WO PCT/US2014/048905 patent/WO2015017545A1/en not_active Ceased
- 2014-07-30 EP EP14832909.7A patent/EP3027776B1/en active Active
- 2014-07-30 CA CA2919690A patent/CA2919690C/en active Active
-
2016
- 2016-02-01 IL IL243894A patent/IL243894B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3027776A4 (en) | 2017-03-08 |
| EP3027776C0 (en) | 2024-02-07 |
| JP6913459B2 (ja) | 2021-08-04 |
| WO2015017545A1 (en) | 2015-02-05 |
| US20150038349A1 (en) | 2015-02-05 |
| EP3027776A1 (en) | 2016-06-08 |
| AU2014296212B2 (en) | 2020-10-22 |
| KR102389934B1 (ko) | 2022-04-21 |
| IL243894B (en) | 2020-06-30 |
| US10378059B2 (en) | 2019-08-13 |
| JP2016526908A (ja) | 2016-09-08 |
| HK1220493A1 (en) | 2017-05-05 |
| IL243894A0 (en) | 2016-04-21 |
| CN105531380B (zh) | 2021-07-13 |
| CA2919690A1 (en) | 2015-02-05 |
| EP3027776B1 (en) | 2024-02-07 |
| CN105531380A (zh) | 2016-04-27 |
| AU2014296212A1 (en) | 2016-02-25 |
| KR20160030535A (ko) | 2016-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shinde et al. | Spleen tyrosine kinase–mediated autophagy is required for epithelial–mesenchymal plasticity and metastasis in breast cancer | |
| Watson et al. | Transcriptomic definition of molecular subgroups of small round cell sarcomas | |
| Wagner et al. | CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival | |
| Kim et al. | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma | |
| Shaw et al. | The early effects of rapid androgen deprivation on human prostate cancer | |
| US9429574B2 (en) | Cancer therapies and methods | |
| CA2819399C (en) | Marker for determination of sensitivity to triplet combination anti-cancer agent | |
| Comert et al. | Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era | |
| Banerjee et al. | Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma | |
| da Silva et al. | Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia | |
| Aitken et al. | Emerging treatment options for patients with p53-pathway-deficient CLL | |
| Harada et al. | TRK inhibitors in non-small cell lung cancer | |
| Thielhelm et al. | Understanding the radiobiology of vestibular schwannomas to overcome radiation resistance | |
| Zhao et al. | Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma | |
| CA2919690C (en) | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate | |
| Johnson et al. | Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma | |
| Song et al. | Cyclin D1 expression in peripheral T-cell lymphomas | |
| Kim et al. | Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045 | |
| Carpanese et al. | Interactomic exploration of LRRC8A in volume-regulated anion channels | |
| Krulikas et al. | Application of integrated drug screening/kinome analysis to identify inhibitors of gemcitabine-resistant pancreatic cancer cell growth | |
| Wu et al. | Single-cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer | |
| Kiura et al. | Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples | |
| Somers et al. | CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements | |
| Tyagi et al. | Insights into existing and futuristic treatment approach for chronic myeloid leukaemia | |
| Khatami et al. | Personalized cancer therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190514 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - SMALL Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250725 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250725 |